Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjögren’s disease

• Amgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic Sjögren's disease.
• The trial met its primary goal, showing a meaningful reduction in overall systemic disease activity that emerged quickly then held through 48 weeks.
• Safety was broadly consistent with expectations, with mostly mild-to-moderate side effects and low discontinuation rates.
• Detailed results have not yet been presented; Amgen plans to disclose the full dataset at an upcoming medical meeting.
• A second Phase 3 study in a different Sjögren's population is expected to finish in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53425) on September 22, 2026, and is solely responsible for the information contained therein.